RecombinantRabMAb

Recombinant Anti-PEX19 antibody [EPR9266(B)] (ab137072)

Reviews (1) Submit a question References (8)
Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
  • Immunocytochemistry/ Immunofluorescence - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
  • Flow Cytometry - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
  • Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
  • Immunoprecipitation - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
  • Anti-PEX19 antibody [EPR9266(B)] (ab137072)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR9266(B)] to PEX19
  • Suitable for: Flow Cyt, IP, ICC/IF, WB
  • Reacts with: Rat, Human

Overview

  • Product name

    Anti-PEX19 antibody [EPR9266(B)]
    See all PEX19 primary antibodies

  • Description

    Rabbit monoclonal [EPR9266(B)] to PEX19

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    ICC/IF
    Human
    IP
    Human
    WB
    Rat
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human PEX19 aa 1-100. The exact sequence is proprietary.
    Database link: P40855

  • Positive control

    • Jurkat, rat brain lysate, rat heart and MOLT4 cell lysates; Jurkat cells.

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab137072 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Guaranteed

Tested applications are guaranteed to work and covered by our Abpromise guarantee.

Predicted

Predicted to work for this combination of applications and species but not guaranteed.

Incompatible

Does not work for this combination of applications and species.

Application Species
Flow Cyt
Human
ICC/IF
Human
IP
Human
WB
Rat
Human
Application Abreviews Notes
Flow Cyt
1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
IP
1/10 - 1/100.
ICC/IF
1/50 - 1/100.
WB (1)
1/1000 - 1/10000. Predicted molecular weight: 33 kDa.
Notes
Flow Cyt
1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
IP
1/10 - 1/100.
ICC/IF
1/50 - 1/100.
WB
1/1000 - 1/10000. Predicted molecular weight: 33 kDa.
  • Application notes
    Is unsuitable for IHC-P.

    • Target

    • Function

      Necessary for early peroxisomal biogenesis. Acts both as a cytosolic chaperone and as an import receptor for peroxisomal membrane proteins (PMPs). Binds and stabilizes newly synthesized PMPs in the cytoplasm by interacting with their hydrophobic membrane-spanning domains, and targets them to the peroxisome membrane by binding to the integral membrane protein PEX3. Excludes CDKN2A from the nucleus and prevents its interaction with MDM2, which results in active degradation of TP53.

    • Tissue specificity

      Ubiquitously expressed. Isoform 1 is strongly predominant in all tissues except in utero where isoform 2 is the main form.

    • Involvement in disease

      Defects in PEX19 are the cause of peroxisome biogenesis disorder complementation group 14 (PBD-CG14) [MIM:600279]; also known as PBD-CGJ. PBD refers to a group of peroxisomal disorders arising from a failure of protein import into the peroxisomal membrane or matrix. The PBD group is comprised of four disorders: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum. The PBD group is genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies.
      Defects in PEX19 are a cause of Zellweger syndrome (ZWS) [MIM:214100]. ZWS is a fatal peroxisome biogenesis disorder characterized by dysmorphic facial features, hepatomegaly, ocular abnormalities, renal cysts, hearing impairment, profound psychomotor retardation, severe hypotonia and neonatal seizures. Death occurs within the first year of life.

    • Sequence similarities

      Belongs to the peroxin-19 family.

    • Cellular localization

      Cytoplasm. Peroxisome membrane. Mainly cytoplasmic. Some fraction membrane-associated to the outer surface of peroxisomes.
    • Information by UniProt

    • Database links

      • Alternative names

        • 33 kDa housekeeping protein antibody
        • D1S2223E antibody
        • HK33 antibody
        • Housekeeping gene 33kD antibody
        • OK/SW-cl.22 antibody
        • PBD12A antibody
        • Peroxin 19 antibody
        • Peroxin-19 antibody
        • Peroxisomal biogenesis factor 19 antibody
        • Peroxisomal farnesylated protein antibody
        • PEX19 antibody
        • PEX19_HUMAN antibody
        • PMP1 antibody
        • PMPI antibody
        • PXF antibody
        • PXMP1 antibody
        see all

      Images

      • Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        All lanes : Anti-PEX19 antibody [EPR9266(B)] (ab137072) at 1/1000 dilution (Purified)

        Lane 1 : Jurkat (Human T cell leukemia T lymphocyte) whole cell lysates with 5% NFDM/TBST
        Lane 2 : MOLT-4 (Human lymphoblastic leukemia T lymphoblast) whole cell lysates with 5% NFDM/TBST

        Lysates/proteins at 20 µg per lane.

        Secondary
        All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)

        Predicted band size: 33 kDa
        Observed band size: 35,40 kDa
        why is the actual band size different from the predicted?



        The doublets are reported by PMID: 9339377, 28817674 and 10051604
      • Immunocytochemistry/ Immunofluorescence - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Immunocytochemistry/ Immunofluorescence - Anti-PEX19 antibody [EPR9266(B)] (ab137072)

        Immunocytochemistry/ Immunofluorescence analysis of MOLT-4 (Human lymphoblastic leukemia T lymphoblast) cells labeling PEX19 with Purified ab137072 at 1:100 (10.2 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1:200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1:1000 (2 µg/ml) dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

      • Flow Cytometry - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Flow Cytometry - Anti-PEX19 antibody [EPR9266(B)] (ab137072)

        Flow Cytometry analysis of A549 (Human lung carcinoma epithelial cell) cells labeling PEX19 with purified ab137072 at 1:100 dilution (10 µg/ml) (red). Cells were fixed with 4% Paraformaldehyde. A Goat anti rabbit IgG (Alexa Fluor® 488) secondary antibody was used at 1:2000 dilution. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).

      • Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Western blot - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        All lanes : Anti-PEX19 antibody [EPR9266(B)] (ab137072) at 1/2000 dilution (Purified)

        Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
        Lane 2 : Rat brain lysates with 5% NFDM/TBST
        Lane 3 : Rat heart lysates with 5% NFDM/TBST

        Lysates/proteins at 20 µg per lane.

        Secondary
        All lanes : Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

        Predicted band size: 33 kDa
        Observed band size: 35,40 kDa why is the actual band size different from the predicted?



        The doublets are reported by PMID: 9339377, 28817674 and 10051604
      • Immunoprecipitation - Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Immunoprecipitation - Anti-PEX19 antibody [EPR9266(B)] (ab137072)

        ab137072 (purified) at 1:50 dilution (2µg) immunoprecipitating PEX19 in MOLT-4 whole cell lysate.
        Lane 1 (input): MOLT-4 (Human lymphoblastic leukemia T lymphoblast) whole cell lysate 10µg
        Lane 2 (+): ab137072 & MOLT-4 whole cell lysate
        Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab137072 in MOLT-4 whole cell lysate
        For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1:1000 dilution.
        Blocking and diluting buffer: 5% NFDM/TBST.

      • Anti-PEX19 antibody [EPR9266(B)] (ab137072)
        Anti-PEX19 antibody [EPR9266(B)] (ab137072)

      References (8)

      Publishing research using ab137072? Please let us know so that we can cite the reference in this datasheet.

      ab137072 has been referenced in 8 publications.

      • Covill-Cooke C  et al. Peroxisomal fission is modulated by the mitochondrial Rho-GTPases, Miro1 and Miro2. EMBO Rep 21:e49865 (2020). PubMed: 31894645
      • Paudel I  et al. Sab concentrations indicate chemotherapeutic susceptibility in ovarian cancer cell lines. Biochem J 475:3471-3492 (2018). PubMed: 30322886
      • Wyant GA  et al. mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient. Cell 171:642-654.e12 (2017). PubMed: 29053970
      • Sychev ZE  et al. Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLoS Pathog 13:e1006256 (2017). PubMed: 28257516
      • Wolfson RL  et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature 543:438-442 (2017). PubMed: 28199306
      • Wang W  et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med 22:869-78 (2016). PubMed: 27348499
      • Schrul B & Kopito RR Peroxin-dependent targeting of a lipid-droplet-destined membrane protein to ER subdomains. Nat Cell Biol 18:740-51 (2016). PubMed: 27295553
      • Chen WW  et al. Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell 166:1324-1337.e11 (2016). PubMed: 27565352

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      Western blot abreview for Anti-PEX19 antibody [EPR9266(B)]

       Good
      Abreviews
      abreview image
      Application
      Western blot
      Sample
      Human Cell lysate - whole cell (HEK293T cells)
      Gel Running Conditions
      Reduced Denaturing (5% stacking and 10% separating Bis-Tris gel)
      Loading amount
      270000 cells
      Specification
      HEK293T cells
      Blocking step
      Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
      Read More

      Ms. Tamara Somborac

      Verified customer

      Submitted Feb 16 2018

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com